Suraksha Diagnostic working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
81.01×81.01×99.52×
21.50×21.50×20.00×
172.64×172.64×168.70×
−70.13×−70.13×−49.18×
111.19×106.04×56.82×
0.79×0.79×0.76×
2.61×2.61×2.05×
0.86×0.86×0.78×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SURAKSHA₹319.55

Suraksha Diagnostic Limited

· Pharma & Health
₹ CrorePeersKRSNAAHEALTHXNEPHROPLUS3BBLACKBIOMcap ₹1,664 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)99.5281.0181.01
Receivable Days (DSO)20.0021.5021.50
Payable Days (DPO)168.70172.64172.64
Cash Conversion Cycle (days)-49.18-70.13-70.13
Working Capital Turnover56.82106.04111.19
Asset Turnover0.760.790.79
Cash Conversion (CFO/Net Income)2.052.612.61
CFO/EBITDA0.780.860.86
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.